CALI:CA:CNSX-FinCanna Capital Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 0.10

Change

0.00 (0.00)%

Market Cap

CAD 0.01B

Volume

0.06M

Average Target Price

CAD 0.20 (+100.00%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

FinCanna Capital Corp. operates as a royalty company for the licensed cannabis industry in the United States. It provides financing for companies operating in the cannabis sector. The company has royalty agreements with Green Compliance Inc.; QVI, Inc.; and Cultivation Technologies, Inc. FinCanna Capital Corp. was incorporated in 2016 is headquartered in Vancouver, Canada. Address: 800 West Pender Street, Vancouver, BC, Canada, V6C 2V6

Currency: CAD

Country : Canada

Technical Indicators

Beta : 0.99

52 Week High : 0.13

Short Ratio : 1.03

52 Week Low : 0.04

Shorted Shares : 94,775

200 Day Moving Average : 0.08

Shorted Shares Previous Month : 4,160

50 Day Moving Average : 0.07

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GTII:CA Green Thumb Industries Inc

+0.60 (+1.67%)

 CAD7.78B N/A 46.07
TER:CA TerrAscend Corp

+0.03 (+0.17%)

 CAD1.28B N/A N/A
PLTH:CA Planet 13 Holdings Inc

-0.19 (-2.62%)

 CAD1.20B N/A 185.60
LHS:CA Liberty Health Sciences Inc

-0.02 (-1.65%)

 CAD0.41B 39.67 6.18
RWB:CA Red White & Bloom Brands Inc

N/A

 CAD0.21B N/A N/A
CXXI:CA C21 Investments Inc

-0.05 (-2.94%)

 CAD0.18B N/A N/A
ROMJ:CA Rubicon Organics Inc

+0.10 (+2.99%)

 CAD0.14B N/A N/A
ROMJ:CA Rubicon Organics Inc

+0.10 (+2.99%)

 CAD0.14B N/A N/A
ROMJ:CA Rubicon Organics Inc

+0.10 (+2.99%)

 CAD0.14B N/A N/A
ROMJ:CA Rubicon Organics Inc

+0.10 (+2.99%)

 CAD0.14B N/A N/A

ETFs Containing CALI:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.00% 68% D+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.00% 68% D+ 69% D+
Trailing 12 Months  
Capital Gain 5.26% 40% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.26% 40% F 32% F
Trailing 5 Years  
Capital Gain 11.11% 51% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.11% 51% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain -15.20% 59% F 28% F
Dividend Return N/A 67% D+ 52% F
Total Return -15.20% 59% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 21.57% 97% A+ 93% A
Risk Adjusted Return -70.48% 39% F 14% F
Market Capitalization 0.01B 32% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 85.00 15% F 13% F
Price/Book Ratio 1.00 73% C 85% B
Price / Cash Flow Ratio -6.56 51% F 36% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.75% 53% F 50% F
Return on Invested Capital -11.30% 78% C+ 73% C
Return on Assets -60.12% 8% F 29% F
Debt to Equity Ratio 0.85% 78% C+ 64% D
Technical Ratios  
Short Ratio 1.03 16% F 20% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.99 63% D 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.